ClinicalTrials.gg
RecruitingNCT07608926DIGITAL PREVUpdated May 27, 2026

Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model

An interventional study of Recommendations to the patient. in Cardiovascular (CV) Risk, sponsored by Maria Cecilia Hospital. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Maria Cecilia Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2025, registered Apr 2026).
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.

This study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.

02

Conditions studied

  • Cardiovascular (CV) Risk

Keywords

  • Cardiovascular risk factors
  • Prevention
03

In context

Lead sponsor

Maria Cecilia Hospital is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40 and 75 years
  • hypertension
  • hyperglycaemia
  • type 2 diabetes not requiring insulin therapy
  • dyslipidaemia
  • active smoking
  • overweight/grade I obesity
  • Willingness to participate in follow-up visits over 24 months

Exclusion criteria

Exclusion Criteria:

  • previous myocardial infarction
  • stroke
  • coronary artery diseas
  • peripheral arterial occlusive disease
  • heart failure
  • Type 1 or type 2 diabetes mellitus on insulin therapy
  • Advanced chronic kidney disease ( \< 30 mL/min/1.73 m²)
  • Active cancer disease
  • Severe obesity
  • Inability to use digital tools
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Digital technology

    Remote management of study participants, enabling the structured collection of relevant information for follow-up.

    Other: Recommendations to the patient.

  • Other
    on site

    adherence to in-person follow-up at the hospital.

    Other: Recommendations to the patient.

Interventions

  • OtherRecommendations to the patient.

    Recommendations to the patient

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Systolic and diastolic in millimeters of mercury

    Time frame: 12 months

  2. number of cigarettes

    Time frame: 24 months

Secondary outcomes

  1. body weigh

    Time frame: 24 months

  2. number of daily steps

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 27, 2026
StartActual
May 28, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608926
Lead sponsor
Maria Cecilia Hospital
Responsible party
Sponsor
First posted
May 27, 2026
Start date
May 28, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion